🔎 Trials Near Me

Home › Vaping › NCT06765291

Behavioral Intervention for Youth to Promote Vaping Cessation

Recruiting

Who can join

Ages 14 to 19 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Age 14-19 inclusive
* Self-report of at least weekly nicotine vaping (or use of other non combusted nicotine products, "vaping") for the prior ≥3 months
* Self-report of no regular combusted tobacco use (i.e., 5 or more days of smoke smoked tobacco use per week) prior to enrollment and exhaled CO \<10 ppm for those with an in person baseline visit
* Report willingness to try to quit or reduce vaping in the next 30 days
* Able to understand study procedures and read and write in English or Spanish
* Have a parent or legal guardian who is able to participate in the opt out process
* Competent and willing to provide written informed consent (if age 18) or assent (if under 18)

Exclusion Criteria:

* Use of a smoking cessation medication in the prior month (nicotine patch, gum, nasal spray, or inhaler, varenicline, bupropion)
* Unwilling to abstain during the study from using smoking cessation aids other than those provided by the study
* Unwilling to provide saliva or urine samples
* Any condition or situation that would, in the investigator's opinion, make it unlikely that the participant could adhere safely to the study protocol

About the study

This study will test the hypothesis that the QuitVaping (QV) intervention and additional texting support will improve nicotine abstinence rates in adolescents as compared to Enhanced Usual Care (EUC: education about nicotine, vaping and addiction, advice to quit vaping, referral to TIQ texting support). Approximately 400 adolescents will be randomly assigned to one of two arms (1) QuitVaping intervention plus texting support to quit vaping and (2) EUC only.

What is being tested

Sponsor: Massachusetts General Hospital · Participants: 400 · Started: Jun 18, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT06765291

Locations in the U.S.

MassachusettsMassachusetts General Hospital, Center for Addiction Medicine, 101 Merrimac Street, Suite 320, Boston, MA 02114, Boston

Conditions

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.